ESPR stock forecast
Our latest prediction for Esperion Therapeutics, Inc.'s stock price was made on the Jan. 23, 2020 when the stock price was at 51.84$.
In the short term (2weeks), ESPR's stock price should outperform the market by 1.23%. During that period the price should oscillate between -9.94% and +10.68%.
In the medium term (3months), ESPR's stock price should underperform the market by -5.06%. During that period the price should oscillate between -39.81% and +27.81%.Get email alerts
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
At the moment the company generates 147M USD in revenues.
On its last earning announcement, the company reported a loss of -3.54$ per share.
The book value per share is 6.56$
Three months stock forecastJan. 23, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|